Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBALON vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
FDA-approved: Relief of redness and itching of the eye due to minor eye irritations (e.g., smoke, dust, wind, swimming, or wearing contact lenses).,Off-label: Treatment of allergic conjunctivitis symptoms (as an adjunct).
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.
1.34 mg (one capsule) orally twice daily.
Terminal elimination half-life is 4-6 hours; clinically, dosing every 6-8 hours is recommended, with adjustments in renal impairment
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Primarily metabolized in the liver via oxidative deamination by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT).
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary/fecal elimination (10-15%)
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Approximately 99% bound to serum albumin and alpha-1-acid glycoprotein
92% bound to albumin.
0.5-0.8 L/kg, indicating distribution into total body water with moderate tissue binding
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Oral: 60-70% due to first-pass metabolism; Ophthalmic: negligible systemic absorption (<1%)
Oral: 68% ± 12% due to first-pass metabolism.
No dosage adjustment required; systemic absorption minimal.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
No dosage adjustment required; not studied in hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
Children ≥3 years: same as adult dosing; children <3 years: safety and efficacy not established.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
No specific adjustment; use with caution due to possible increased sensitivity to anticholinergic effects.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
No FDA black box warning.
None.
Use with caution in patients with cardiovascular disease (e.g., hypertension, arrhythmias) or hyperthyroidism due to systemic absorption.,Prolonged use may lead to rebound congestion (rhinitis medicamentosa) if used intranasally; ocular overuse may cause reactive hyperemia.,Avoid in patients with narrow-angle glaucoma (risk of angle closure).,Monitor for systemic effects (e.g., dizziness, headache, palpitations).
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Hypersensitivity to naphazoline or any component of the formulation.,Narrow-angle glaucoma (absolute contraindication).,Patients with severe cardiovascular disease (e.g., uncontrolled hypertension, coronary insufficiency).,Concomitant use with MAO inhibitors or within 14 days of MAO inhibitor therapy (risk of hypertensive crisis).
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
No specific food interactions; however, avoid alcohol as it may exacerbate ocular irritation or dizziness.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited human data; animal studies not evaluated for malformations. Second/third trimester: possible fetal hypoxia due to vasoconstriction; avoid use near term due to risk of neonatal tachycardia, hypertension, and irritability.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
No human data on excretion in breast milk. M/P ratio unknown. Naphazoline likely passes into milk due to low molecular weight; risk of infant vasoconstrictive effects if absorbed. Use with caution; avoid prolonged or high-dose use while breastfeeding.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
No dose adjustment recommended for topical ophthalmic use. Systemic absorption is negligible; however, if systemic effects occur, reduce frequency. Pregnancy may alter ocular pharmacokinetics, but no specific adjustment data available.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
ALBALON (naphazoline/pheniramine) ophthalmic solution: Use with caution in patients with cardiovascular disease or hypertension due to naphazoline's alpha-adrenergic effects; limit use to 3-4 days to avoid rebound conjunctival hyperemia; do not use in patients with narrow-angle glaucoma; remove contact lenses before instillation and wait 15 minutes before reinserting.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Do not use while wearing soft contact lenses; remove lenses before using and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not use more than 4 times daily or for longer than 72 hours without consulting a doctor; overuse can cause worsening redness.,Temporary stinging or blurred vision may occur upon instillation; do not drive until vision clears.,Seek medical attention if eye pain, vision changes, or persistent redness occur.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBALON vs ACTAHIST, answered by our medical review team.
ALBALON is a Ophthalmic Antihistamine/Decongestant that works by Naphazoline is an imidazoline derivative that acts as a direct-acting sympathomimetic amine, stimulating alpha-adrenergic receptors in the conjunctival arterioles, resulting in vasoconstriction and decreased congestion.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBALON and ACTAHIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBALON is: 1-2 drops in affected eye(s) every 3-4 hours; frequency may be increased to every 2 hours in severe cases.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBALON and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBALON is classified as Category C. AUX: Category C. Naphazoline is an imidazoline sympathomimetic with potential for vasoconstriction; systemic absorption may reduce uterine blood flow. First trimester: limited huma. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.